Home › Crohn's Disease › California › Orange
Crohn's Disease clinical trials in Orange, CA
4 studies for Crohn's Disease are looking for participants at sites in and around Orange (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
RecruitingPhase 3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 5128), Orange
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
RecruitingPhase 2
- UCI Health, Orange
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
RecruitingPhase 3
- Children's Hospital Of Orange County, Orange
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
RecruitingPhase 3
- Children's Hospital of Orange County, Orange
About Crohn's Disease
Crohn's Disease can cause inflammation in any area from the mouth to the anus. Read about medicines, surgery or dietary management to treat symptoms.
More about Crohn's Disease on MedlinePlus
Crohn's Disease trials in other cities
- New York City, NY35 studies
- Miami, FL19 studies
- St. Louis, MO19 studies
- Boston, MA19 studies
- Cleveland, OH18 studies
- Houston, TX17 studies
- Orlando, FL17 studies
- Atlanta, GA17 studies
- Tyler, TX16 studies
- San Diego, CA15 studies
- San Antonio, TX15 studies
- Los Angeles, CA15 studies
Other studies in Orange
- Non-Small Cell Lung Cancer25 studies
- Metastatic Cancer20 studies
- Colorectal Cancer16 studies
- Ovarian Cancer16 studies
- Pancreatic Cancer15 studies
- Lung Cancer14 studies
- Cancer (all types)14 studies
- Melanoma14 studies
- Prostate Cancer14 studies
- Breast Cancer14 studies
- Liver Cancer (Hepatocellular Carcinoma)14 studies
- Stomach Cancer13 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.